Free Trial
NASDAQ:OSA

ProSomnus (OSA) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$0.03
$0.03
50-Day Range
$0.02
$0.66
52-Week Range
$0.35
$5.25
Volume
800 shs
Average Volume
65,686 shs
Market Capitalization
$530,517.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.33
OSA stock logo

About ProSomnus Stock (NASDAQ:OSA)

ProSomnus, Inc. operates as a medical technology company that develops, manufactures, and markets precision intraoral medical devices for treating and managing patients with obstructive sleep apnea. The company sells its products to sleep dentists, sleep physicians, primary care providers, otolaryngologists, and other integrated healthcare service providers through a direct sales force. ProSomnus, Inc. is headquartered in Pleasanton, California.

OSA Stock News Headlines

Q4 2023 Prosomnus Inc Earnings Call
ProSomnus Inc OSA
ProSomnus Treatment for Sleep Apnea Effective, Study Shows
See More Headlines
Receive OSA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ProSomnus and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
5/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:OSA
Fax
N/A
Employees
136
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$2.33
High Stock Price Target
$4.00
Low Stock Price Target
$1.00
Potential Upside/Downside
+8,203.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$-24,090,000.00
Pretax Margin
-87.14%

Debt

Sales & Book Value

Annual Sales
$27.65 million
Book Value
($2.33) per share

Miscellaneous

Free Float
16,055,000
Market Cap
$488,771.40
Optionable
Not Optionable
Beta
0.21
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for June 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Leonard Liptak (Age 49)
    Co-Founder, CEO & Director
    Comp: $965.35k
  • Mr. Sung Kim (Age 42)
    Co-Founder & CTO
    Comp: $454.63k
  • Ms. Laing F. Rikkers
    Co-founder & Executive Chairman
  • Mr. Brian B. Dow (Age 55)
    CFO & Corporate Secretary
  • Dr. John E. Remmers M.D.
    Chief Scientist
  • Ms. Heather Whalen
    Vice President of Global Marketing Services
  • Dr. Shouresh Charkhandeh D.D.S.
    Global Scientific Committee Chair

OSA Stock Analysis - Frequently Asked Questions

Should I buy or sell ProSomnus stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ProSomnus in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" OSA shares.
View OSA analyst ratings
or view top-rated stocks.

What is ProSomnus' stock price target for 2024?

3 equities research analysts have issued twelve-month price objectives for ProSomnus' shares. Their OSA share price targets range from $1.00 to $4.00. On average, they anticipate the company's share price to reach $2.33 in the next twelve months. This suggests a possible upside of 7,550.3% from the stock's current price.
View analysts price targets for OSA
or view top-rated stocks among Wall Street analysts.

This page (NASDAQ:OSA) was last updated on 5/29/2024 by MarketBeat.com Staff

From Our Partners